Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia
Key facts
- Who runs it
- Chinese PLA General Hospital
- Where
- China4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Early phase 1
- People taking part
- 250 people, planned
- Started
- 1 Jun 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- YHDF placebo
- Bacteriophage Placebo
- YHDF Drug
- Bacteriophage
- Record updated
- 29 May 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Patients who meet the diagnostic criteria for severe pneumonia caused by drug-resistant Gram-negative bacilli and conform to the TCM syndrome differentiation of Qi deficiency, toxin accumulation and blood stasis syndrome
- Patients confirmed by rapid on-site microbiological evaluation (M-ROSE), clinical microbial culture and drug susceptibility testing (based on the drug susceptibility test results of our hospital or other Grade A tertiary hospitals) to be infected with multidrug-resistant Klebsiella pneumoniae, Acinetobacter baumannii or Pseudomonas aeruginosa
- Aged 18 to 85 years old
- Patients or their family members agree to cooperate with the collection of upper and lower respiratory tract specimens, consent to bronchoscopy plus bronchoalveolar lavage, and agree to receive nebulized inhalation of bacteriophage therapy
- Patients or their family members have fully read, understood and signed the informed consent form
Who cannot take part
- Patients receiving immunosuppressive therapy or suffering from immunodeficiency diseases
- Patients who have received mechanical ventilation for more than 60 days prior to enrollment
- Patients with active pulmonary tuberculosis, lung abscess, or Grade D chronic obstructive pulmonary disease (COPD)
- Patients with known allergies to bacteriophage products or the components of Yiqi Huoxue Jiedu Formula
- Women who are pregnant or lactating
- Patients with immunodeficiency
- Patients with incomplete sampling or clinical data
- Patients judged by the researchers as unsuitable for participation in this study
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Pneumonia
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Through a prospective randomized controlled trial, we systematically evaluate the effects of Yiqi Huoxue Jiedu Formula combined with bacteriophage therapy on the bacterial clearance rate, disease improvement rate and mortality rate in patients with severe pneumonia caused by drug-resistant bacteria, so as to clarify its clinical transformation value.
The 4 groups in the trial
- YHDF Placebo + Bacteriophage Placebo GroupPlacebo, for comparison
7-14 days treatment with YHDF placebo, 7-14 days treatment with phage placebo
Treatment: YHDF placebo and Bacteriophage Placebo
- YHDF Placebo + Bacteriophage GroupExisting treatment, for comparison
7-14 days treatment with YHDF placebo, 7-14 days treatment with phage placebo
Treatment: YHDF placebo and Bacteriophage
- YHDF Drug + Bacteriophage Placebo GroupExisting treatment, for comparison
7-14 days treatment with YHDF, 7-14 days treatment with phage placebo
Treatment: Bacteriophage Placebo and YHDF Drug
- YHDF Drug + Bacteriophage GroupExisting treatment, for comparison
7-14 days treatment with YHDF, 7-14 days treatment with phage
Treatment: YHDF Drug and Bacteriophage
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli
- Criteria questions
- Built from NCT07612605, who can take part
- Record updated
- 29 May 2026